Once again, how we presently use BRAF and KRAS inhibitors in the clinical setting in CRC relies on this tumors' unique biology, marking a clear difference compared to other malignancies such as melanoma or non‐small cell lung cancer [15]. Here, KRAS is linked to colorectal carcinoma.